Clinical Trial Detail

NCT ID NCT03200717
Title Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

clear cell renal cell carcinoma

Therapies

Pazopanib

Age Groups: adult senior

No variant requirements are available.